A few questions came to mind! 
-How does the company measure its strategic goals in practice? The current main goals do not include numerical targets, so I assume the company has internal KPIs linked to these goals below? Can you elaborate on these?
-The company has stated it focuses on creating a foundation for growth during its strategy period; now that we are moving into the final year of the strategy period, how does Jouni assess the company’s success, and what will the focus be during 2026?
-How sensitive are Revenio’s customers in the USA to uncertainty? Some of the medtech companies I follow have already reported their results, and the figures are very varied. For some, government shutdowns have made a significant dent in sales because the customers are public labs, etc. Others, on the other hand, have accelerated growth in the USA. How would Jouni assess how customer behavior changes as uncertainty increases?
-What kind of pricing models does Revenio have for its software solutions? Does the new iCare ALTIUS, for example, generate new revenue, or are these provided for the customer’s use alongside product purchases?
-Is a decline in multiples observable among potential acquisition targets?
I assume Juha will inquire about how the recovery of Private Equity-driven customers is looking, and if there are changes from the previous quarter .
Jouni referred to R&D projects in the pipeline during the Q3 interview that might increase FDA costs. Any possible additional information regarding these would be interesting.
A question for Juha: are APAC sales direct or through a partner?